XmAb 2513

Drug Profile

XmAb 2513

Alternative Names: XmAb®2513

Latest Information Update: 10 Jul 2013

Price : $50

At a glance

  • Originator Xencor
  • Class Antineoplastics; Immunoglobulins; Monoclonal antibodies
  • Mechanism of Action CD30 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hodgkin's disease
  • Discontinued T cell lymphoma

Most Recent Events

  • 10 Jul 2013 XmAb 2513 is still in phase I development for Hodgkin's disease in USA
  • 17 Nov 2010 Clinical development of XmAb 2513 is ongoing in USA
  • 02 Jun 2009 Interim efficacy, pharmacokinetics and adverse events data from a phase I trial in Hodgkin's disease presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top